OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) major shareholder Jennifer Pritzker sold 22,500 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $23.35, for a total transaction of $525,375.00. Following the completion of the sale, the insider owned 6,504,133 shares in the company, valued at $151,871,505.55. This represents a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
OrthoPediatrics Stock Performance
NASDAQ:KIDS opened at $22.41 on Friday. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $585.13 million, a P/E ratio of -13.34 and a beta of 0.99. The firm has a 50-day moving average price of $21.78 and a two-hundred day moving average price of $18.87. OrthoPediatrics Corp. has a twelve month low of $14.42 and a twelve month high of $26.74.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The business had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. As a group, research analysts expect that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.
Hedge Funds Weigh In On OrthoPediatrics
Analyst Ratings Changes
Several brokerages have recently issued reports on KIDS. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. BTIG Research increased their target price on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Needham & Company LLC lifted their target price on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Truist Financial set a $22.00 price target on OrthoPediatrics in a research report on Wednesday, August 5th. Finally, TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $26.44.
Check Out Our Latest Stock Analysis on KIDS
About OrthoPediatrics
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Read More
- Five stocks we like better than OrthoPediatrics
- MarketBeat Week in Review – 08/31 – 09/04
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
